PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
3986.96%
Revenue growth exceeding 1.5x AGEN's 28.03%. David Dodd would verify if faster growth reflects superior business model.
No Data
No Data available this quarter, please select a different quarter.
804.39%
Gross profit growth exceeding 1.5x AGEN's 50.03%. David Dodd would verify competitive advantages.
117.23%
Margin expansion exceeding 1.5x AGEN's 60.97%. David Dodd would verify competitive advantages.
-19.33%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-34.65%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.37%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-24.37%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.46%
EBITDA growth 1.25-1.5x AGEN's 31.66%. Bruce Berkowitz would examine sustainability.
98.45%
EBITDA margin growth exceeding 1.5x AGEN's 46.63%. David Dodd would verify competitive advantages.
35.83%
Similar operating income growth to AGEN's 34.36%. Walter Schloss would investigate industry trends.
98.43%
Operating margin growth exceeding 1.5x AGEN's 48.74%. David Dodd would verify competitive advantages.
-7.89%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
35.97%
Pre-tax income growth 1.25-1.5x AGEN's 25.15%. Bruce Berkowitz would examine sustainability.
98.43%
Pre-tax margin growth exceeding 1.5x AGEN's 41.54%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
36.40%
Net income growth exceeding 1.5x AGEN's 3.12%. David Dodd would verify competitive advantages.
98.44%
Net margin growth exceeding 1.5x AGEN's 24.33%. David Dodd would verify competitive advantages.
37.84%
EPS growth exceeding 1.5x AGEN's 3.16%. David Dodd would verify competitive advantages.
37.84%
Diluted EPS growth exceeding 1.5x AGEN's 2.58%. David Dodd would verify competitive advantages.
2.81%
Share count increase while AGEN reduces shares. John Neff would investigate differences.
2.81%
Diluted share increase while AGEN reduces shares. John Neff would investigate differences.